ibuprofen has been researched along with Dyspepsia in 9 studies
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine
Dyspepsia: Impaired digestion, especially after eating.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study sought to evaluate dyspepsia-related health in osteoarthritis (OA) and rheumatoid arthritis (RA) patients taking valdecoxib compared with patients taking nonspecific NSAIDs." | 9.11 | Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis. ( Goldstein, JL; Mayne, TJ; Rabeneck, L; Rublee, DA; Vu, A, 2005) |
| "To analyse major sources of evidence-based information on the efficacy and gastrointestinal tolerability of aspirin, used short-term, in over-the-counter (OTC) doses, to relieve acute pain and cold symptoms, including associated feverishness." | 8.88 | Efficacy and gastrointestinal risk of aspirin used for the treatment of pain and cold. ( McCarthy, DM, 2012) |
| "Acetylsalicylic acid (ASA [aspirin]) is a commonly used over-the-counter drug for the treatment of pain, fever, or colds, but data on the safety of this use are very limited." | 8.87 | Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. ( Baron, JA; Brueckner, A; Lanas, A; McCarthy, D; Senn, S; Voelker, M, 2011) |
| " Adverse events (AEs) were collected beginning at the first dose and continued through completion (54 weeks)." | 6.80 | One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia. ( Ball, J; Bello, AE; Grahn, AY; Holt, RJ; Kent, JD, 2015) |
| "In the pivotal efficacy and safety trials, discontinuation rates due to any cause and dyspepsia were significantly lower for the ibuprofen/famotidine combination versus ibuprofen alone." | 5.20 | One-year safety of ibuprofen/famotidine fixed combination versus ibuprofen alone: pooled analyses of two 24-week randomized, double-blind trials and a follow-on extension. ( Ball, J; Bello, AE; Grahn, AY; Holt, RJ; Kent, JD, 2015) |
| " This study sought to evaluate dyspepsia-related health in osteoarthritis (OA) and rheumatoid arthritis (RA) patients taking valdecoxib compared with patients taking nonspecific NSAIDs." | 5.11 | Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis. ( Goldstein, JL; Mayne, TJ; Rabeneck, L; Rublee, DA; Vu, A, 2005) |
| "To analyse major sources of evidence-based information on the efficacy and gastrointestinal tolerability of aspirin, used short-term, in over-the-counter (OTC) doses, to relieve acute pain and cold symptoms, including associated feverishness." | 4.88 | Efficacy and gastrointestinal risk of aspirin used for the treatment of pain and cold. ( McCarthy, DM, 2012) |
| "Acetylsalicylic acid (ASA [aspirin]) is a commonly used over-the-counter drug for the treatment of pain, fever, or colds, but data on the safety of this use are very limited." | 4.87 | Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. ( Baron, JA; Brueckner, A; Lanas, A; McCarthy, D; Senn, S; Voelker, M, 2011) |
| " Adverse events (AEs) were collected beginning at the first dose and continued through completion (54 weeks)." | 2.80 | One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia. ( Ball, J; Bello, AE; Grahn, AY; Holt, RJ; Kent, JD, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bello, AE | 2 |
| Kent, JD | 2 |
| Grahn, AY | 2 |
| Ball, J | 2 |
| Holt, RJ | 2 |
| Taha, AS | 1 |
| Lanas, A | 1 |
| McCarthy, D | 1 |
| Voelker, M | 1 |
| Brueckner, A | 1 |
| Senn, S | 1 |
| Baron, JA | 1 |
| McCarthy, DM | 1 |
| Goldstein, JL | 2 |
| Zhao, SZ | 1 |
| Burke, TA | 1 |
| Palmer, R | 1 |
| von Allmen, H | 1 |
| Henderson, SC | 1 |
| Hollenz, M | 1 |
| Labenz, J | 1 |
| Rabeneck, L | 1 |
| Vu, A | 1 |
| Mayne, TJ | 1 |
| Rublee, DA | 1 |
| Gupta, S | 1 |
| McQuaid, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open-Label Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-Steroidal Anti-Inflammatory Drug Treatment[NCT00984815] | Phase 3 | 86 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The non-pain symptom scale of the SODA questionnaire ranges from 7 - 35. Change from baseline compares the score at Week 54 to the baseline score for each participant that completed the non-pain symptom questions of the SODA questionnaire at baseline and Week 54. Higher scores indicate greater symptom severity and therefore a negative mean change from baseline is indicative of an improvement in symptoms. (NCT00984815)
Timeframe: Baseline and 54 Weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| HZT-501 | -1.44 |
The pain intensity scale of the SODA questionnaire ranges from 2 - 47. Change from baseline compares the score at Week 54 to the baseline score for each participant who completed the pain intensity questions of the SODA questionnaire at baseline and Week 54. Higher scores indicate greater symptom severity and therefore a negative mean change from baseline is indicative of an improvement in symptoms. (NCT00984815)
Timeframe: Baseline and 54 Weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| HZT-501 | -3.22 |
The satisfaction with dyspepsia-related health scale of the SODA questionnaire ranges from 2 - 23. Change from baseline compares the score at Week 54 to the baseline score for each participant who completed the Satisfaction questions of the SODA questionnaire at baseline and Week 54. A positive change from baseline in the SODA satisfaction scale represents a participant's overall improved satisfaction with their dyspepsia-related health. (NCT00984815)
Timeframe: Baseline and 54 Weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| HZT-501 | 2.69 |
(NCT00984815)
Timeframe: 54 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 76 |
2 reviews available for ibuprofen and Dyspepsia
| Article | Year |
|---|---|
Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials.
Topics: Acetaminophen; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Common Cold; Double-Blind Me | 2011 |
Efficacy and gastrointestinal risk of aspirin used for the treatment of pain and cold.
Topics: Acetaminophen; Aspirin; Common Cold; Dyspepsia; Fever; Gastrointestinal Tract; Humans; Ibuprofen; No | 2012 |
3 trials available for ibuprofen and Dyspepsia
| Article | Year |
|---|---|
One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Combinations; Drug | 2015 |
One-year safety of ibuprofen/famotidine fixed combination versus ibuprofen alone: pooled analyses of two 24-week randomized, double-blind trials and a follow-on extension.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Combinations; Drug | 2015 |
Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Diclofena | 2005 |
4 other studies available for ibuprofen and Dyspepsia
| Article | Year |
|---|---|
The ibuprofen-famotidine combined pill - a promise fulfilled.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dyspepsia; Famotidine; Female; Histamine H2 Antagonists; Hu | 2015 |
Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States.
Topics: Abdominal Pain; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhi | 2003 |
[Gastrointestinal complications under NSAID treatment in the doctor's office].
Topics: Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Clinical Trials as Topic; Dicl | 2004 |
Management of nonsteroidal, anti-inflammatory, drug-associated dyspepsia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cyclooxygenase 2 Inhibitors; Dyspepsia; | 2005 |